CRISPR Therapeutics AG NGM · CRSP
Price alert —
Sign in to get a one-time email the moment CRSP crosses your price. Free accounts included.
Sign in / create a free accountCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRSP last traded at $48.15, up 2.5% on the day; that's in the lower part of its 52-week range ($44.12–$63.45). Right now it's dipped below its recent average — a spot where watchers often look for signs the dip is stabilizing.
The next scheduled earnings report (2026-05-11) is the biggest known catalyst on the calendar, and after the recent dip, watch whether the price stops making lower lows before assuming the worst is over.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 lower, -1.40 ATR from EMA21 — bullish engulfing
- · KC1 lower stretch — light dip
- · Bullish engulfing — body fully covers prior red bar
- · RSI hook from oversold (39)
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · Aligned with weak downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 38), the trend is quiet (ADX 23), and trading is light at 0.6× normal volume. On the business side, revenue is growing 69% year over year.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
The model's verdict is “Unknown” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.
- ✓ More cash than debt
- ✓ Quick ratio 16.37 (antifragile)
- ✓ Current ratio 13.32 (antifragile)
- ✓ Debt/equity 0.18 (antifragile)
- ⚠ Negative retained earnings
CRSP is a $4.7 billion company, it moves harder than the market (beta 1.7).
Options idea
See more →Earnings
See more →- Last reported
- 2026-05-04
- EPS (act / est)
- -1.28 / -1.23
- Surprise
- -3.7%
- Next report
- 2026-08-10
About
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It …